• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

USDA Grants Canine Osteosarcoma Vaccine With Conditional License

January 6, 2018
American Veterinarian Editorial Staff

A new canine osteosarcoma vaccine has been granted a conditional license and will be tested among 2 dozen veterinary oncology groups. With enough success, the vaccine could be given a full license and unrestricted distribution in the United States.

Osteosarcoma is the most common primary bone tumor in dogs, but a new vaccine is striving to change that narrative. Aratana Therapeutics, a company focused on innovative therapeutics for dogs and cats, announced that their Canine Osteosarcoma Vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the United States Department of Agriculture (USDA) Center for Veterinary Biologics.

The vaccine uses a listeria-based antigen delivery system that activates cytotoxic T-cells. This directs the T-cells to fight off cancer cells—capitalizing on the dog’s immune system and its ability to attack bacterial infections.

"We know that most of these dogs relapse with metastatic disease, so clearly cancer is left after chemotherapy," said Nicola J. Mason, BVetMed, PhD, assistant professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine and principal investigator of clinical trials investigating the new vaccine. "And we were asking the question: Could this vaccine induce an immune response which would eliminate those remaining cancer cells?”

During a clinical trial, researchers evaluated 18 dogs with primary tumor removal and gave them 4 doses of carboplatin chemotherapy followed by the new canine osteosarcoma vaccine every 3 weeks for 3 doses. The median survival rate was 956 days with the vaccine, compared with 423 days in a historical control group.

Common side effects reported included lethargy, diarrhea, and fever; only 4 serious adverse events were reported in a separate field safety study.

Advertisement

“Since there haven't been advances to raise the standard of care in nearly 20 years, dogs often face a poor prognosis," said Ernst Heinen, DVM, PhD, chief development officer of Aratana Therapeutics. "We are hopeful that our canine osteosarcoma vaccine will be a new tool for veterinary oncologists to prolong survival in dogs with osteosarcoma."

The new vaccine will be made available for purchase at approximately 24 veterinary oncology practice groups across the United States who will participate in a new extended field study. Aratana plans to conduct this study early this year as part of the USDA requirement for products to progress from a conditional license to a full license.

If the new study receives successful results, the USDA may approve the vaccine and allow unrestricted sales throughout the United States.

"This technology is very exciting for everyone; it's something completely new," Dr. Heinen said.


Advertisement

Latest News

Freshpet and Petco partner launch fresh pet food subscription

AAHA Con heads to San Diego

VHMA announces latest class of CVPMs

Jaguar undergoes anesthesia to determine cause of appetite loss

View More Latest News
Advertisement